Cancer Therapy News and Research

RSS

Adenovirus used to destroy cancer cells

With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.

23 Jun 2007

Sea-squirt derived drug trabectedin shows promise as cancer treatment

The sea-squirt derived drug trabectedin (ecteinascidinin-743) shows anti-tumour activity in more than half of patients with a specific type of cancer, conclude authors of an article published early Online and in the July edition of The Lancet Oncology.

22 Jun 2007

Microfluidic chip for cancer diagnosis

For the first time an important diagnostic test for cancer has been miniaturized and automated onto a microfluidic chip by a team of University of Alberta researchers in Edmonton, Canada.

20 Jun 2007

Noninvasive treatment of cancer tumors

Ram Devireddy, assistant professor of mechanical engineering at LSU, recently co-authored an article with Todd Monroe, assistant professor of biological and agricultural engineering, investigating the complex effects of nanoparticles on cell freezing.

18 Jun 2007

Hormone therapy can extend life in ovarian cancer patients

The study, published in Clinical Cancer Research, has proved for the first time that the targeted use of an anti-oestrogen drug could prolong the life of some patients by up to three years, and delay the use of chemotherapy in others.

17 Jun 2007

New area of stroke drug discovery for the 22nd century

A new therapy to re-activate silenced genes in patients who suffer from neurodegenerative diseases or stroke is being developed by researchers at the University of Illinois at Chicago and Cornell University.

17 Jun 2007

Diagnosing cancer at early stages imperative for survival

Early detection of cancer through regular screenings can greatly increase survival rates because it identifies cancer when it's most treatable, according to the National Cancer Institute.

17 Jun 2007

Gene implicated in the development of cancer cells can be switched on using drugs

A gene implicated in the development of cancer cells can be switched on using drugs, report researchers from the University of Michigan Comprehensive Cancer Center.

16 Jun 2007

Trial shows nanoparticle-enabled thermal therapy safe for treating cancer

Several types of metal nanoparticles are capable of converting energy, such as that carried by near-infrared light or an oscillating magnetic field, into heat at a level high enough to kill tumors.

14 Jun 2007

New contributor to aggressive cancers

Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study published in the Journal of the National Cancer Institute.

8 Jun 2007

New drug-delivery system using nanomaterials

Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.

8 Jun 2007

Scientists look at slow-freezing techniques for human tissue

The goal is to make human eggs, ovarian tissue, blood vessels, even whole organs available when needed.

8 Jun 2007

Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases

Pediatricians now have a practical tool to help determine whether children with chronic diseases like Crohn's, juvenile arthritis and anorexia nervosa or those undergoing cancer treatment are at increased risk for bone mass deficiencies, fracture or osteoporosis as they get older, according to a new study whose lead author is a researcher at Cincinnati Children's Hospital Medical Center.

8 Jun 2007

How exercise helps people with cancer

A cancer diagnosis doesn't dictate the end of exercise and activity.

8 Jun 2007

Blocking the action of beta1-integrin to treat cancer

Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in the EMBO Journal.

8 Jun 2007

Vorinostat shows anti-cancer activity in recurrent gliomas

North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme.

5 Jun 2007

Bone-targeting radioisotope radium-223 for prostate cancer treatment

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Gabapentin reduces hot flashes in men receiving androgen deprivation therapy

North Central Cancer Treatment Group ( http://ncctg/ ) researchers based at Mayo Clinic ( http://www.mayo.edu/ ) in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.

5 Jun 2007

Herceptin does not increase heart failure in patients long-term

Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007